Results 51 to 60 of about 164,596 (212)

Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors. [PDF]

, 2014
BackgroundIn 31 solid tumor patients treated with the demethylating agent decitabine, we performed tumor biopsies before and after the first cycle of decitabine and used immunohistochemistry (IHC) to assess whether decitabine increased expression of ...
A Kumari, AS Yang, C Festuccia, C Zeller, CA Stidley, CJ Piyathilake, D Ma, D Matei, D Shang, DJ Stewart, DJ Stewart, DJ Stewart, DJ Stewart, DJ Stewart, DJ Stewart, DW Shen, E Gordian, E San Jose-Eneriz, EA Braga, F Crea, F Fang, H Iwata, H Kantarjian, H Kroeger, HM Kantarjian, J Charlet, J Shia, JA Plumb, JP Issa, JP Issa, JS Kim, K Ghoshal, K Onda, K Ramachandran, K Tikoo, KY Tse, L Ding, L Rothem, MA Kane, ML Orta, NH Nabilsi, R Zhao, RH Finnell, S Fu, S Vijayaraghavalu, SB Baylin, SS Muerkoster, T Tanaka, TB Lee, VF Chekhun, X Chang, XJ Liang, Y Li, Y Oki, Y Zhang, ZG Liu   +55 more
core   +2 more sources

Aurora-A contributes to cisplatin resistance and lymphatic metastasis in non-small cell lung cancer and predicts poor prognosis [PDF]

, 2014
BACKGROUND: Platinum-based chemotherapy improves survival among patients with non-small cell lung cancer (NSCLC), but the efficiency is limited due to resistance.
An-wen Liu, Cai-feng Yue, Jie Xu, Quentin Liu, Shao-wu Wang, Wei-hua Zhou, Yan Zhang, Yuan-min Qian   +7 more
core   +2 more sources

AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through cross-talk with the STAT1/3 signaling pathway

Journal of Experimental & Clinical Cancer Research, 2019
Background Cisplatin is the first-line chemotherapy used against most upper aerodigestive tract carcinomas. In head and neck cancer, sensitivity to cisplatin remains the key issue in treatment response and outcome. Genetic heterogeneity and aberrant gene
Wei-Min Chang, Yu-Chan Chang, Yi-Chieh Yang, Sze-Kwan Lin, Peter Mu-Hsin Chang, Michael Hsiao   +5 more
doaj   +1 more source

Controlling platinum, ruthenium, and osmium reactivity for anticancer drug design [PDF]

, 2009
The main task of the medicinal chemist is to design molecules that interact specifically with derailed or degenerating processes in a diseased organism, translating the available knowledge of pathobiochemical and physiological data into chemically ...
Bruijnincx, Pieter C. A., Sadler, P. J.
core   +1 more source

Development of taxane resistance in a panel of human lung cancer cell lines [PDF]

, 2008
Using a selection process designed to reflect clinically relevant conditions, a panel of taxane-selected variants were developed to study further the mechanisms of resistance in lung cancer.
Breen, Laura, Clynes, Martin, Keenan, Joanne, Murphy, Lisa   +3 more
core   +1 more source

New extracellular resistance mechanism for cisplatin

Journal of Inorganic Biochemistry, 2008
The HSQC NMR spectrum of 15N-cisplatin in cell growth media shows resonances corresponding to the monocarbonato complex, cis-[Pt(NH3)2(CO3)Cl](-), 4, and the dicarbonato complex, cis-[Pt(NH3)2(CO3)2](-2), 5, in addition to cisplatin itself, cis-[Pt(NH3)2Cl2], 1. The presence of Jurkat cells reduces the amount of detectable carbonato species by (2.8+/-0.
Centerwall, Corey R, Kerwood, Deborah J, Goodisman, Jerry, Toms, Bonnie B, Dabrowiak, James C   +4 more
openaire   +3 more sources

Glutathione S‐transferase omega class 1 (GSTO1)‐associated large extracellular vesicles are involved in tumor‐associated macrophage‐mediated cisplatin resistance in bladder cancer

Molecular Oncology
Bladder cancer poses a significant challenge to chemotherapy due to its resistance to cisplatin, especially at advanced stages. Understanding the mechanisms behind cisplatin resistance is crucial for improving cancer therapy.
Yi‐Cheng Pan, Pei‐Yi Chu, Ching‐Chan Lin, Ching‐Yun Hsieh, Wei‐Yu Hsu, Lie‐Fen Shyur, Juan‐Cheng Yang, Wei‐Chao Chang, Yang‐Chang Wu   +8 more
doaj   +1 more source

Transforming Growth Factor Alpha Stimulation of Mucosal Tissue Cultures from Head and Neck Squamous Cell Carcinoma Patients Increases Chemoresistance to Cisplatin [PDF]

, 2010
The monoclonal epidermal growth factor receptor ( EGFR) antibody cetuximab (Erbitux(TM)) was recently approved by the European Medicines Agency for the treatment of recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) in combination ...
Baumeister, Philipp, Harreus, Ulrich, Reiter, Maximilian, Schwenk-Zieger, Sabina   +3 more
core   +1 more source

Active Efflux System for Cisplatin in Cisplatin‐resistant Human KB Cells [PDF]

Japanese Journal of Cancer Research, 1994
Mutants, KCP‐4 and PC‐5, resistant to an anticancer agent, cisplatin, were selected in multiple steps from human epidermoid KB carcinoma cells and human prostate PC‐3 carcinoma cells, respectively. KCP‐4 and PC‐5 were 63 and 10 fold more resistant to cisplatin than the parental cells, respectively.
Fujii, Ryu‐ichi, Mutoh, Masato, Niwa, Kiyoshi, Yamada, Kazutaka, Aikou, Takashi, Nakagawa, Masayuki, Kuwano, Michihiko, Akiyama, Shin‐ichi   +7 more
openaire   +2 more sources

VANGL2 downregulates HINT1 to inhibit the ATM-p53 pathway and promote cisplatin resistance in small cell lung cancer

Cell Death Discovery
Cisplatin is a first-line drug for the treatment of small cell lung cancer (SCLC). Although the majority of patients with SCLC initially respond to cisplatin therapy, cisplatin resistance readily develops, leading to tumor progression.
Jiayi Xie, Huiying Liu, Chunqian Yang, Weitao Shen, Jian Zhang   +4 more
doaj   +1 more source